Marker Therapeutics (NASDAQ:MRKR) Raised to “Hold” at Wall Street Zen

Marker Therapeutics (NASDAQ:MRKR) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

MRKR has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. HC Wainwright initiated coverage on Marker Therapeutics in a research note on Monday, December 8th. They set a “buy” rating and a $10.00 target price for the company. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 18th. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.17.

Marker Therapeutics Stock Up 3.4%

Shares of Marker Therapeutics stock opened at $1.54 on Friday. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07. The stock has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.21. The stock has a market capitalization of $25.67 million, a P/E ratio of -1.25 and a beta of 1.37.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The business had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. Sell-side analysts anticipate that Marker Therapeutics will post -0.65 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

Several institutional investors have recently modified their holdings of the company. Two Sigma Investments LP bought a new stake in shares of Marker Therapeutics during the third quarter valued at approximately $33,000. Virtu Financial LLC bought a new position in Marker Therapeutics in the third quarter worth $25,000. Finally, Jane Street Group LLC acquired a new stake in Marker Therapeutics during the second quarter worth $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.